Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.
The risk of Clostridium difficile infection (CDI) in hospitalized patients may be halved by a strategy of administering probiotics within 2 days of antibiotic initiation, according to the results of a systematic review.
Bezlotoxumab, a human monoclonal antibody against Clostridium difficile (C. difficile) toxin B, appears to reduce the risk of recurrent C. difficile infection, according to findings from the MODIFY I* and MODIFY II** trials.
Foecal microbiota transplantation (FMT) done through the lower gastrointestinal (LGI) delivery route appears to be the most effective way for the prevention of recurrence/relapse of Clostridium difficile infection (CDI), suggests a study.
Transfer of sterile filtrates, rather than faecal microbiota, from donor stool may be enough to restore normal stool habits and eliminate symptoms in patients with Clostridium difficile infection (CDI), according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Vancomycin is similarly effective and superior to metronidazole for the treatment of mild and severe Clostridium difficile infections, respectively, as presented in a systematic review and meta-analysis of 17 studies.
Adding intravenous metronidazole may be beneficial in critically ill patients with Clostridium difficile infection receiving oral vancomycin, as exhibited in a single-centre, retrospective, observational, comparative study.
Children with autism spectrum disorders (ASD) appear to have significantly altered gut mucosal mitochondrial function compared with controls and other children with nonspecific gastrointestinal symptoms, a recent study shows.
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.